NewsBenzingaCitigroup mantiene il rating Buy su Caris Life Sciences, alza il prezzo obiettivo a 36 dollari Citigroup mantiene il rating Buy su Caris Life Sciences, alza il prezzo obiettivo a 36 dollari Benzinga 2026.11.06 21:25 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says